Information Provided By: 
Fly News Breaks for November 17, 2016
ELGX
Nov 17, 2016 | 08:57 EDT
As noted earlier, BMO Capital downgraded Endologix to Market Perform from Outperform. After the FDA requested two year data on the company's Nelix device instead of one year data, analyst Joanne Wuensch now expects the device to be approved in 2Q18 instead of 3Q17. Target to $9.50 from $14.
News For ELGX From the Last 2 Days
There are no results for your query ELGX
